Wegovy Legal and Patent Challenges

FDA Approval Timeline and Regulatory Pathway

The FDA approved Wegovy on June 4, 2021, under a new drug application (NDA 215256) for chronic weight management in adults with obesity or overweight plus at least one weight-related comorbidity [1]. The approval rested primarily on the STEP clinical trial program, a series of four Phase 3 trials enrolling over 4,500 participants across multiple countries.

Semaglutide had already received FDA approval at lower doses (0.25 mg to 1.0 mg) under the brand name Ozempic for type 2 diabetes in December 2017. The 2.4 mg dose required a separate NDA because obesity represented a distinct therapeutic indication with different dosing, titration schedules, and target populations. The FDA granted priority review but not breakthrough therapy designation, reflecting the established mechanism of GLP-1 receptor agonism rather than a novel pharmacological approach [2].

The regulatory timeline moved quickly by historical standards. Novo Nordisk submitted the NDA in December 2020 and received approval six months later. This pace reflected the strength of the STEP-1 data: in 1,961 participants, semaglutide 2.4 mg produced a 14.9% mean reduction in body weight at 68 weeks compared with 2.4% for placebo (P<0.001) [3]. The effect size exceeded that of previously approved anti-obesity medications by a wide margin.

Patent Portfolio and Exclusivity Strategy

Novo Nordisk holds a complex web of patents protecting semaglutide, spanning the compound itself, formulation methods, dosing regimens, device delivery systems, and methods of treatment. The base compound patent (covering the semaglutide molecule) is the most commercially significant, with expiration dates varying by jurisdiction but generally extending into the early 2030s.

The company's patent strategy for Wegovy specifically includes claims on the 2.4 mg dose, the five-step titration protocol (0.25 mg for 4 weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg), and the prefilled pen delivery device. This layered approach creates what intellectual property attorneys call a "patent thicket," where generic or biosimilar manufacturers must challenge multiple patents simultaneously to bring a competing product to market [4].

No Paragraph IV certifications for generic semaglutide 2.4 mg had been filed with the FDA as of early 2026. The Orange Book lists multiple patents covering Wegovy, and the combination of compound protection, formulation patents, and regulatory exclusivity periods creates a multi-year window before generic competition becomes feasible.

Compounding Pharmacy Litigation

The most contentious legal battles have involved compounding pharmacies. When the FDA placed semaglutide on its Drug Shortage List in March 2022, Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act permitted licensed compounding pharmacies to produce copies of drugs in shortage without holding an approved NDA [5].

Novo Nordisk responded aggressively. The company filed lawsuits against multiple compounding pharmacies and wellness clinics in 2023 and 2024, alleging trademark infringement, false advertising, and violations of state pharmacy practice acts. The core legal argument: compounded semaglutide is not equivalent to Wegovy, patients face safety risks from non-FDA-approved formulations, and compounders were capitalizing on the Wegovy brand name to market their products.

Compounding pharmacies countered with several defenses. They argued that federal law explicitly permits compounding during shortages, that semaglutide is a well-characterized small peptide amenable to compounding, and that Novo Nordisk's supply failures created the legal opening in the first place. Several cases settled confidentially; others remained in active litigation through 2025.

The FDA's February 2024 announcement that semaglutide injection was no longer in shortage changed the calculus. Once a drug exits the shortage list, compounders lose their Section 503A/503B protections for that specific product. Novo Nordisk issued cease-and-desist letters to hundreds of compounding pharmacies within weeks of that announcement, and the company's legal team described the enforcement campaign as protecting patient safety [6].

Label Evolution and Safety Communications

The Wegovy prescribing information has undergone significant revisions since initial approval. The original 2021 label carried a boxed warning regarding medullary thyroid carcinoma (MTC) risk based on rodent data with GLP-1 receptor agonists. Semaglutide caused dose-dependent thyroid C-cell tumors in rats and mice at clinically relevant exposures [7]. The warning states that Wegovy is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Additional labeled warnings include acute pancreatitis, acute gallbladder disease, hypoglycemia when used with insulin or sulfonylureas, acute kidney injury, hypersensitivity reactions, diabetic retinopathy complications in patients with type 2 diabetes, and suicidal behavior or ideation. The suicidality language was strengthened in January 2024 following FDA review of post-marketing adverse event reports, though the agency stated it had not confirmed a causal relationship [8].

The most significant label expansion came in March 2024 when the FDA added a cardiovascular risk reduction indication based on the SELECT trial (N=17,604). SELECT demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% compared with placebo in adults with established cardiovascular disease and overweight or obesity but without diabetes (HR 0.80; 95% CI 0.72-0.90; P<0.001) [9]. This made Wegovy the first anti-obesity medication to carry a cardiovascular benefit indication.

The SELECT Trial and Its Regulatory Impact

SELECT changed how regulators, insurers, and prescribers view anti-obesity pharmacotherapy. The trial enrolled participants aged 45 years or older with BMI ≥27, established cardiovascular disease (prior myocardial infarction, stroke, or peripheral arterial disease), and no diabetes. The primary endpoint was time to first occurrence of cardiovascular death, nonfatal MI, or nonfatal stroke.

Over a mean follow-up of 39.8 months, semaglutide reduced the composite MACE endpoint from 8.0% (placebo) to 6.5% (treatment), representing a number needed to treat (NNT) of 67 over approximately 3.3 years [9]. The trial also showed reductions in heart failure hospitalization, all-cause mortality (though not statistically significant as a prespecified endpoint), and confirmed the weight loss efficacy seen in earlier STEP trials.

For regulators, SELECT provided the cardiovascular safety data that had historically been a barrier for obesity drugs. Previous anti-obesity agents (fenfluramine, sibutramine) were withdrawn due to cardiovascular harm. SELECT flipped this narrative entirely by showing cardiovascular benefit, giving the FDA grounds to expand the indication and giving Novo Nordisk a stronger commercial and legal position [10].

Insurance Coverage and Access Disputes

Legal challenges extend beyond patent litigation into the insurance and coverage arena. Despite FDA approval and the SELECT cardiovascular data, many insurers and pharmacy benefit managers (PBMs) continue to exclude Wegovy from formularies or impose extensive prior authorization requirements. Medicare Part D explicitly excluded coverage of anti-obesity medications under the statutory "weight loss drug" exclusion until the Treat and Reduce Obesity Act gained momentum in Congress [11].

Novo Nordisk has pursued legal and regulatory strategies to expand access. The cardiovascular indication creates a pathway for coverage under medical benefit rather than pharmacy benefit in some plans, because cardiovascular risk reduction is not "weight loss" per se. Several class-action lawsuits have been filed by patients against insurers alleging that denial of Wegovy coverage after SELECT constitutes failure to cover medically necessary treatment.

State-level legislation has also created a patchwork of coverage requirements. As of early 2026, at least 11 states had introduced or passed bills requiring state-regulated health plans to cover FDA-approved anti-obesity medications. These laws face their own legal challenges from insurance industry groups arguing that coverage mandates increase premiums and exceed state regulatory authority.

International Regulatory Divergence

Wegovy's regulatory path has not been uniform globally. The European Medicines Agency (EMA) approved Wegovy in January 2022 through a centralized marketing authorization, but supply constraints delayed actual market availability in most EU member states until 2023 or 2024 [12]. The EMA's Committee for Medicinal Products for Human Use (CHMP) required additional pharmacovigilance measures not mandated by the FDA, including a registry study to monitor thyroid cancer incidence in European patients.

Health Canada approved Wegovy in November 2022. Australia's Therapeutic Goods Administration (TGA) followed in October 2023. Each regulatory authority applied somewhat different labeling requirements. The TGA, for instance, imposed a more restrictive BMI threshold (≥30 only, without the ≥27-with-comorbidity option) at initial approval.

These international differences create legal complexity for Novo Nordisk's global patent strategy and for patients seeking cross-border access. Personal importation of Wegovy from countries with lower pricing has generated enforcement questions, particularly along the U.S.-Canada border where price differentials can exceed 50%.

Post-Marketing Surveillance and Safety Signals

The FDA's Sentinel System and the agency's Adverse Event Reporting System (FAERS) have generated ongoing post-marketing safety data that intersects with Wegovy's legal profile. Reported adverse events of interest include ileus/intestinal obstruction, aspiration events during anesthesia (due to delayed gastric emptying), and the previously mentioned suicidality signal [13].

The American Society of Anesthesiologists issued guidance in 2023 recommending that patients hold GLP-1 receptor agonists prior to elective procedures requiring anesthesia, citing case reports of aspiration. This created liability questions for prescribers and surgeons regarding informed consent and perioperative management protocols.

Novo Nordisk established a post-marketing commitment with the FDA to conduct a five-year observational study assessing thyroid cancer risk, a requirement attached to the 2021 approval. Interim data has not shown a statistically significant increase in MTC in semaglutide-treated patients compared with background rates, but the study remains ongoing [14].

The European Pharmacovigilance Risk Assessment Committee (PRAC) conducted a signal assessment of GLP-1 receptor agonists and suicidal ideation in 2023-2024, ultimately concluding that available evidence did not confirm a causal association but recommending continued monitoring. This regulatory conclusion differs subtly from the FDA's label language, creating transatlantic divergence in how prescribers communicate risk.

Future Legal and Regulatory Considerations

Several pending regulatory and legal developments will shape Wegovy's market position through the end of the decade. Novo Nordisk's next-generation obesity agent, CagriSema (cagrilintide plus semaglutide), completed Phase 3 trials in 2025 and may receive approval in 2026-2027. The relationship between CagriSema and Wegovy patents raises questions about evergreening strategies and whether regulatory approval of the combination product extends effective market exclusivity for semaglutide-based therapies [15].

The FDA's 2024 draft guidance on peptide drug products and their eligibility for compounding under 503B outsourcing facilities remains under debate. If finalized as drafted, the guidance could narrow the legal basis for semaglutide compounding even during future shortages by establishing stricter standards for demonstrating pharmaceutical equivalence.

Patent challenge filings (ANDA Paragraph IV or biosimilar applications under the BPCIA) could appear as early as 2027-2028, depending on how courts interpret the scope of Novo Nordisk's dosing-method and device patents. The timeline for actual biosimilar semaglutide reaching patients likely extends to 2032 or beyond, given the combination of patent litigation timelines, FDA review periods, and potential 30-month stays.

Patients prescribed Wegovy at the standard 2.4 mg maintenance dose should discuss any coverage changes, supply concerns, or compounded alternatives with their prescribing clinician rather than independently switching formulations, as bioequivalence between branded Wegovy and compounded semaglutide preparations has not been established by the FDA.